Leading employers share strategies for managing promising, high-cost biotech medications
Companies and organizations nationwide struggle to find the best way to address the complex, multifaceted challenges involved in providing their employees with access to necessary--and often expensive--medications. The introduction of new bio-derived medications has compounded these challenges. Biot...
Gespeichert in:
Veröffentlicht in: | The American journal of managed care 2008-07, Vol.14 (8 Suppl), p.S264-S268 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Companies and organizations nationwide struggle to find the best way to address the complex, multifaceted challenges involved in providing their employees with access to necessary--and often expensive--medications. The introduction of new bio-derived medications has compounded these challenges. Biotech medications offer a high level of therapeutic value, but do so at a high monthly cost per patient. Employers are developing new and innovative approaches to benefit design in an effort to protect their organization's assets, yet develop a benefit design that provides therapeutic value to all employees. This article outlines strategies that some of the nation's leading employers have incorporated into their benefit programs. |
---|---|
ISSN: | 1936-2692 |